AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$TEVA

Weiss Amir sold $355K of TEVA

Weiss Amir (Chief Accounting Officer) sold 9,445 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at an average of $37.62 ($37.61–$37.63, $0.36M total) across 2 trades on 2026-08-21.

Original reporting
SEC EDGAR · Weiss Amir
Published Aug 25, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEVA
Neutral
high confidence
Mentioned
$TEVA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

Minimal impact; typical for routine insider sales of this magnitude.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential tax planning or portfolio rebalancing; not material to valuation.

Relevance 4/10Novelty 4/10Timing: filed today (2026-08-25)

Background

SEC Form 4 filing discloses insider transactions; used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$TEVANeutralHigh confidence
Context

Chief Accounting Officer Weiss Amir sold 9,445 shares for $355,301, reducing his stake to 13,071 shares.

Expected impact

Minor downward pressure, likely negligible.

Evidence & confidence

Sale size is modest relative to market cap; no broader implications.

Market effects

Sector

None; insider sale does not affect pharma sector broadly.

Regional

None; limited to TEVA shareholders.

Global

Low; isolated insider transaction.

Counterpoint

What could challenge this read

Sale could signal internal concerns, but size is too small to infer.

Key entities

  • Officer
    Weiss Amir

    Chief Accounting Officer of TEVA

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

$TEVAMed

Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call Highlights

Teva Pharmaceutical (TEVA) reported a 2% revenue decline in Q3 2026, driven by a 16% drop in generics revenue. The company discontinued a Phase II study and faces challenges with AUSTEDO revenue due to pricing pressures. CEO Richard Francis and CFO Eli Kalif discussed gross margin expansion, IRA impact, and growth drivers like UZEDY, AJOVY, and WELTRUZA. Teva expects AUSTEDO to reach $2.5B in 2027 and over $3B at peak, despite litigation risks and biosimilar challenges.

finance.yahoo.com
$TEVAHighAI 8/10

H.C. Wainwright raises Teva Pharma stock price target to $54

H.C. Wainwright raised Teva's (NYSE:TEVA) price target to $54 from $52, citing strong Q3 results. Revenue was $4.395B (down 2% YoY, up 6% sequentially), and EPS was $0.86 (beating estimates). The company raised its full-year revenue guidance to $16.7B-$17.0B. Austedo, Ajovy, and Uzedy drove higher expectations. BofA Securities also raised its target to $48.

investing.com
$TEVAMed

Teva’s $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires

Teva and Samsung Bioepis agreed to a $420M deal for two biosimilars. Teva gains US rights to RENFLEXIS (infliximab-abda), which can be sold immediately, and ETICOVO (etanercept-ykro), blocked from US sales until 2029 due to patent disputes. The deal includes upfront, launch, and sales milestones. Teva aims to leverage its distribution network to boost RENFLEXIS's market share, while ETICOVO's launch is delayed by legal restrictions.

techtimes.com